J B Chemicals & Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 14 May 2025, inter alia, have recommended the final dividend of Rs 7 per equity Share (i.e. 700%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of J B Chemicals & Pharmaceuticals rose 15.48% to Rs 145.69 crore in the quarter ended March 2025 as against Rs 126.16 crore during the previous quarter ended March 2024. Sales rose 10.18% to Rs 949.48 crore in the quarter ended March 2025 as against Rs 861.73 crore during the previous quarter ended March 2024.For the full year,net profit rose 19.35% to Rs 659.58 crore in the year ended March 2025 as against Rs 552.63 crore during the previous year ended March 2024. Sales rose 12.45% to Rs 3917.99 crore in the year ended March 2025 as against Rs 3484.18 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales949.48861.73 10 3917.993484.18 12 OPM %23.8522.99 -26.3425.74 - PBDT239.47205.34 17 1058.43889.83 19 PBT193.03164.60 17 887.39751.51 18 NP145.69126.16 15 659.58552.63 19 Powered by Capital Market - Live News

J B Chemicals & Pharmaceuticals has allotted 65,686 equity shares under ESOS on 05 May 2025. Consequently, the issued, subscribed and paid up capital has increased from 15,56,77,208 equity shares of Re. 1 each to 15,57,42,894 equity shares of Re. 1 each.Powered by Capital Market - Live News

J B Chemicals & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 May 2025.Powered by Capital Market - Live News

J B Chemicals & Pharmaceuticals has received approval from United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA), Bisoprolol Tablets USP, 5 mg, and 10 mg, the generic version of Zebeta (Teva), which is indicated in the management of hypertension.Powered by Capital Market - Live News